Disitamab vedotin (RC48) plus toripalimab for HER2-expressing advanced gastric or gastroesophageal junction and other solid tumours: a multicentre, open label, dose escalation and expansion phase 1 trial
-
Published:2024-02
Issue:
Volume:68
Page:102415
-
ISSN:2589-5370
-
Container-title:eClinicalMedicine
-
language:en
-
Short-container-title:eClinicalMedicine
Author:
Wang Yakun,
Gong Jifang,
Wang Airong,
Wei Jia,
Peng Zhi,
Wang Xicheng,
Zhou Jun,
Qi Changsong,
Liu Dan,
Li Jian,
Lu Ming,
Lu Zhihao,
Cao Yanshuo,
Yuan Jiajia,
Zhang Ruyan,
Fang Jianmin,
Zhang Xiaotian,
Shen LinORCID